News

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...
Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...
NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...
At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.
In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...
March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...
The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...
The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.
Microsoft just turned 50 and there's no better time to revisit Windows logos. Here's a brief on Windows Logo evolution.
With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. The German pharma ...
Merck is forking out $5.85 per share for the California company, a sizeable premium on Immune Design’s share price of around $1.50 in the weeks building up to the deal, and which values it at ...